Skip to search formSkip to main contentSkip to account menu

Goserelin Acetate

Known as: Acetate, Goserelin, D-Ser(bu(t))(6)azgly(10)-LHRH Acetate, Goserelin Acetate [Chemical/Ingredient] 
The acetate salt of a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH). Continuous, prolonged administration of goserelin… 
National Institutes of Health

Related topics

Related topics

11 relations
Drug AllergyEndometriosisGNRHR protein, humanGoserelin 10.8 MG Drug Implant [Zoladex]

Broader (1)

Goserelin

Narrower (1)

Zoladex

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma
Prostate stem cell antigen (PSCA) is a recently identified glycosylphosphatidylinositol (GPI)‐anchored cell surface protein… 
2005
2005
Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection
To determine whether needle size influences a patient's perception of pain, 50 patients requiring hormonal manipulation for… 
1998
1998
Randomized Comparison of Goserelin Acetate versus Mitomycin C plus Goserelin Acetate in Previously Untreated Prostate Cancer Patients with Bone Metastases
In a prospective trial conducted by the Gruppo Onco Urologico Piemontese, newly diagnosed prostate cancer patients with bone… 
Review
1996
Review
1996
Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone…
1995
1995
A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group.
Casodex (Bicalutamide, ICI 176,334) is a potent, non-steroidal, selective anti-androgen with a long half-life allowing once-daily… 
1994
1994
Current clinical studies with a new nonsteroidal antiandrogen, casodex
The efficacy of Casodex® (ICI 176,334; Zeneca Pharmaceuticals, Macclesfield, UK), a nonsteroidal antiandrogen, in the treatment… 
Highly Cited
1993
Highly Cited
1993
Quality of life in patients with prostatic cancer a feasibility study
Background. In recent years, there has been a growing recognition of the need to include parameters representing the patients… 
1993
1993
Long‐term results of danish prostatic cancer group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer
In a multicenter trial conducted by the Danish Prostatic Cancer Group, 264 patients with advanced prostate cancer were randomized… 
1993
1993
Luteinizing hormone‐releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low‐dose diethylstilbestrol
Background. In response to the first administration of a luteinizing hormone‐releasing hormone (LHRH) agonist, the secretion of… 
1990
1990
A new extra long acting depot preparation of the LHRH analogue Zoladex®. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)